CompaniesEsperion Therapeutics (1)

Esperion Therapeutics (1)

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (26)
View all

Total Trials

26

As Lead Sponsor

24

As Collaborator

2

Total Enrollment

21,895

By Phase

PHASE4: 2NA: 1PHASE2: 12PHASE3: 7PHASE1: 3

By Status

COMPLETED: 23RECRUITING: 2UNKNOWN: 1
Clinical Trials Pipeline26 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
Today
NCT02993406
NCT05103254
Hover over trial bars to see details

Recent Trials

NCT06021951Lead Sponsor
Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women
PHASE4Completed
16 participants
Started: Aug 4, 2023 · Completed: Mar 22, 2024
NCT06300450Collaborator
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
NARecruiting
400 participants
Started: Mar 1, 2023 · Completed: Jul 30, 2026
NCT05694260Lead Sponsor
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
PHASE2Completed
31 participants
Started: Jan 12, 2023 · Completed: Jun 4, 2025
NCT05263778Collaborator
Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study
PHASE4Unknown
500 participants
Started: Mar 31, 2022 · Completed: Dec 31, 2023
NCT05103254Lead Sponsor
Bempedoic Acid Pregnancy Surveillance Program
N/ARecruiting
20 participants
Started: Sep 1, 2021 · Completed: May 31, 2032
View all 26 trials →
Related Companies
Pfizer Early 2004 $1
acquired